Latest
industry research report on: Anti-Hypertensive Therapeutics Market :
Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand,
Growth, Segmentation, Parameters, Forecasts
GBI Research, the leading business intelligence provider, has released its latest research: ‘Anti-Hypertensive Therapeutics
in Major Developed Markets to 2020 – Increased Uptake of Combination
Therapies to Offset Effects of Key Patent Expiries ’, which provides
in-depth analysis of hypertension therapeutics market within the eight
major geographies of the US, the top five European countries (the UK,
France, Germany, Spain and Italy), Japan and Canada. The report provides
an estimation of market size for 2013, along with market forecast until
2020. It also covers disease epidemiology, treatment algorithms,
treatment patterns, in-depth analysis of the pipeline, and deal
analysis.
The
value of the hypertension market in the major developed markets
amounted to an estimated $40.0 billion in 2013 and is expected to
decline during the forecast period at a negative Compound Annual Growth
Rate (CAGR) of 0.9% to $37.6 billion in 2020,
with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline
thereafter. The initial growth will be due to the increased penetration
of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor,
Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo,
Valturna), a rise in the prevalence population from 181 million to 190
million at a CAGR of 0.6%, and two new expected launches in the pipeline
(azilsartan + amlodipine, and AHU377+ valsartan). However, due to the
expiry of the exclusivity of major drugs both before and during the
forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012;
Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in
2018), increased generic penetration and a low diagnosis rate, the
market will decline from 2017.
Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/206657
Scope
The
report analyzes treatment usage patterns, market characterization,
pipeline analysis and key licensing and co-development deals in the
hypertension in the major developed markets.
The report includes:
- Disease overview, as well as treatment algorithms and treatment use patterns
- Market size and forecast for the hypertension market from 2013–2020
- Major marketed products for hypertension along with a heat map of product performance
- In-depth pipeline analysis for global pipeline in hypertension along with clinical trial failure rate analysis
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements that could have impact on growth trends
Reasons to Buy
The report will enhance your decision-making capability by allowing you to:
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the hypertension therapeutics market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time
and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve
all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
No comments:
Post a Comment